FDA Adds Guillain-Barré Syndrome Warning to GSK’s Shingles Vaccine

March 29, 2021

The FDA has issued a warning regarding GlaxoSmithKline’s (GSK) shingles vaccines, Shingrix, and said it must include a label warning about the risk of Guillain-Barré syndrome (GBS), a rare disorder.

“In a postmarketing observational study, an increased risk of GBS was observed during the 42 days following vaccination with Shingrix,” the FDA said.

The FDA approved Shingrix in October 2017 as a two-dose regimen for preventing shingles in adults age 50 years and older.

GBS affects the body’s immune system and damages nerve cells, causing muscle weakness and in some cases paralysis.

View today's stories